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Preface 3
The 1998 ‘Annual report on the state of the drugs
problem in the European Union’ is central to the
continued advancement of a concerted knowledge
base on which to build a strategic approach to drug
policy within and beyond the Member States that
constitute the European Union. The EMCDDA both
instigates and reflects improvements in communi-
cation and shared awareness of the extent of drug
problems and the suitability of specific markers as
epidemiological indicators within and between 
nations.
As stated in the declaration on demand reduction
adopted by the United Nations in June 1998 ‘de-
mand reduction programmes should be based on a
regular assessment of the nature and magnitude of
drug use and abuse and drug-related problems in
the population. This is imperative for the identifica-
tion of any emerging trends. Assessments should
be undertaken by States in a comprehensive, sys-
tematic and periodic manner, drawing on results of
relevant studies, allowing for geographical consid-
erations and using similar definitions, indicators
and procedures to assess the drug situation. De-
mand reduction strategies should be built on
knowledge acquired from research as well as les-
sons derived from past programmes. These strate-
gies should take into account the scientific ad-
vances in the field, in accordance with the existing
treaty obligations, subject to national legislation
and the comprehensive multidisciplinary outline of
future activities in drug abuse control’. It is exactly
this approach that is reflected in the work of the
EMCDDA in general, and the content of its annual
report in particular.
Each annual report contributes to a developing un-
derstanding of both the need for monitoring and
the recognition that effective policy is contingent
on a satisfactory and accessible information base.
The EMCDDA is increasingly recognised as an in-
valuable source of information, whose autonomy
and political independence guarantee that its an-
nual reports are viewed as key documents for un-
derstanding the major features of drug problems
and the legal, political and social responses to them
initiated within the European Union. However, each
report also represents a reconfiguration of the cen-
tral themes that address policy and practice-related
concerns and this is most obviously manifested in
Chapter 3 of the 1998 report.
This chapter examines the drug situation in the 10
central and east European countries (CEECs) which
are part of the PHARE project for accession coun-
tries to the EU. As with the 15 Member States, the
goal of the EMCDDA’s project remains twofold — to
report on those existing indicators that provide the
most accurate picture of drug problems and re-
sponses in each nation, while encouraging partici-
pants to improve the quality, reliability, comparabil-
ity and accuracy of the information they gather. Al-
though the EMCDDA is aware of resource restric-
tions, gradual improvements in multi-method 
collection and dissemination remain central to 
the objective of improving communication and
cooperation.
In Chapter 1, a new distinction is made between
current trends and directions (based on a combina-
tion of informal and less systematic sources) and
key epidemiological indicators (structured around
agreed definitions where these are available). Thus,
the current trends section allows the incorporation
of qualitative measures and informed opinions on
recent events, where the pay-off is timeliness rather
than precision. In contrast, in the key indicators sec-
tion, drug trends are slightly less up-to-date, but are
more likely to fulfil scientific criteria of reliability
and validity. The overall objective is to employ a va-
riety of methodologies in establishing a wide-rang-
ing series of images of drug activity and response,
rather than to be over-reliant on snapshots whose
clarity is compromised by their processing time.
However, the EMCDDA’s aim of improving the over-
all quality of data available is evidenced in the
structure of the chapter on demand reduction,
where emphasis is given to those projects which
have been adequately evaluated. Particularly in the
area of primary prevention there is a paucity of sci-
entific evidence, not only in Europe but also inter-
nationally, and so the aim has been to present not
only those projects that appear important and in-
dicative, but also those that make some attempt at
satisfactory evaluation. Thus, while there is thor-
ough consideration of new projects that may shed
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light on the direction, for example, of drug educa-
tion, the EMCDDA approach is to encourage inno-
vation married to systematic and scientific method.
The later chapters emphasise, in particular, the fi-
nancial structures in place. Chapter 7 examines the
data available on public spending in response to
drug problems, with examples given from the limit-
ed data sources available. Chapter 5 outlines the
changes that have occurred in EU spending in the
past year and, in particular, the shifts in the break-
down of spending between money spent within
the Union and that spent internationally. Chapter 6
provides an up-to-date account of more general
global activity and the recent work of the main in-
ternational bodies to combat the drugs problem.
While there is still much work to be done, the suc-
cesses of the last year clearly vindicate the work
of the EMCDDA. The overall role of the Centre has
expanded as a centre of excellence for addiction
information, but the Centre has also become in-
creasingly active in improving the knowledge
base for policy-makers, practitioners and re-
searchers alike. The annual report, as an integral
component of EU activity, not only reflects with
increasing accuracy and clarity the drug situation
in the EU countries, but it increasingly provides
an invaluable basis for initiating systematic re-
search and evaluation carried out comparatively
by the EU and beyond.
We are, however, aware that the EU can be no more
insular than the Member States from which it is
constituted, and the EMCDDA will continue to pro-
mote collaborative endeavour between these
Member States, bodies and organisations whose
work is more international. The EMCDDA is increas-
ingly at the core of the relationship between key
European informants through the national and in-
ternational networks of its focal points and the 
EMCDDA’s Reitox network.
Yet our work is essentially educational, progressive
and proactive — we must promote the role of in-
formation collection, management and dissemina-
tion as the critical base for all policy decision-mak-
ing and it is here that the annual report reflects the
success of the efforts made by both the EMCDDA
and the national focal points. With each annual re-
port, we are conscious of increased impact and
readership and of improvements in comparability
and quality. This is a slow and gradual progress, but
with the continued commitment and goodwill of
contributors, both the quality and impact of the
document will gain further ground.
I hope you find this report both interesting and
useful to you in your work, and that it encour-
ages you to support what we at the EMCDDA are
trying to do. Our success requires your coopera-
tion and we are aware that without the support
and feedback of readers we will be foiled in our
task of striving for clarity and quality. We are
committed to the task of improving awareness
and information and I hope you are stimulated
by our endeavours.
Georges Estievenart
Executive Director
EMCDDA
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This section identifies key emerging trends in drug
use and problems in the EU, gives an overview of the
drug situation and summarises key epidemiological
indicators that permit comparisons in the areas of
prevalence, consequences, characteristics and pat-
terns of use and supply. This information is based on
two approaches to data collection. The indicators are
more systematic and scientific though less up to date,
while information on emerging trends is more timely
but necessarily more qualitative. Both approaches
must be regarded as complementary components of
presenting a more grounded overall picture.
At present, coverage of information across the EU is
still inconsistent, making direct comparisons some-
times misleading. Even where information is avail-
able, cultural and methodological differences be-
tween Member States must be taken into account.
The work of the EMCDDA on implementation of
standardised indicators in the EU will improve this
situation gradually.
Overview
Cannabis. Cannabis is the most commonly used il-
licit drug across the EU, having been tried by be-
tween 5 and 20 to 30 % of the total population and
up to 40 % of younger adults. Recent use is less fre-
quent: 1 to 9 % of the adult population and up to
20 % of young adults have used cannabis in the last
12 months. After rapid increases between 1985 and
1994, levels of quantities seized have recently sta-
bilised. As use is most often intermittent, cannabis
is not very often the primary drug problem (ac-
counting for 2 to 16 % of treatment admissions).
Synthetic drugs. Amphetamine is the second most
used illegal drug in most countries (tried by 1 to 9 %
of the adult population and up to 16 % of young
adults) while Ecstasy has been used by 0.5 to 3.0 %
of the adult population, with moderate increases
over time reported in both substances in school and
population surveys. Fatalities from synthetic drugs
are rare, and treatment is infrequently sought. How-
ever amphetamine problems are more frequently
encountered in Finland, Sweden, Belgium and the
United Kingdom, and are most common among
those whose use is chronic and among injectors (1).
Trends, patterns and prevalence of use
(1) See ‘New trends in synthetic drugs in the European Union’,
EMCDDA Insight series.
Emerging trends in drug use and drug problems
Cannabis: Stable after increases in the early 1990s,
especially in higher prevalence countries, some rise in
others.
Some rise in populations entering treatment, but this
may in part reflect recording practices and other
factors.
Amphetamines: Continuing to rise, likely to be more
significant in future than Ecstasy.
Ecstasy: No longer rising in those Member States
where it appeared earlier and prevalence is higher, but
still rising in others. Some diffusion to other
populations.
Other synthetic drugs: New products reported in some
Member States, but not replacing amphetamines and
Ecstasy.
Cocaine: Modest but steady rise in use, although
prevalence is still low.
Crack remains localised, but some spread in selected
areas.
Heroin: Increases among some synthetic drug users
and other young populations reported by some
Member States.
Problematic patterns of use: Diffusion to small towns
and rural areas reported in some countries.
Deaths: Generally stable or decreasing, although with
some exceptions.
Infectious diseases: Rates of new AIDS cases strongly
declining as a result of new treatments which delay
disease progression. AIDS changing into an indicator
of treatment uptake rather than of HIV infection.
Prevalence of HIV infection stable or declining in most
countries, but continued transmission in young and
new injectors.
Prevalence of hepatitis C infections remains extremely
high.
Cocaine. Quantities of cocaine seized increased
sharply in 1996 although this does not appear to
have influenced price or availability. Between 1 and
3 % of adults have tried cocaine, with use lower
among school age children. Frequent, problematic
use is not common and cocaine is usually men-
tioned as the primary drug in less than 5 % of treat-
ment admissions, while the misuse of crack, prima-
rily in opiate misusing groups, remains a limited
phenomenon.
Heroin and other opiates. Trends in supply, use
and dependence appear relatively constant al-
though there is some evidence of a new generation
of young heroin smokers. Between 0.2 and 0.3 % of
the EU population are addicted to opiates, lower
than many other illicit drugs but responsible for
disproportionate social costs in terms of criminal
justice, health, social welfare and mortality. There is
some evidence that heroin is diffusing both geo-
graphically (from cities to rural areas) and socio-
culturally. Opiates are the primary problem drug 
in most treatment centres, and are associated with
most acute drug-related deaths.
Other substances. Solvents are often the second
most abused substances by adolescents. Misuse by
adults of medicines such as benzodiazepines, often
in combination with alcohol, is reported to be 
increasing.
Drugs and health. The strongest link between illi-
cit use and health damage is among injectors. Drug
injectors are significantly more likely to contract
blood-borne diseases (AIDS, hepatitis). While rates
of AIDS have levelled the extreme levels of hepati-
tis C may have serious public health implications.
The number of acute drug-related deaths is gener-
ally stable or decreasing, although with exceptions.
In most cases opiates are involved.
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New areas of development
A priority for the EMCDDA and national focal points is
to improve the timeliness and relevance of information,
to make information more useful to policy-makers, by:
1. extending coverage beyond institutional sources
and research studies to include more informal or
unconventional sources;
2. improving existing indicators, and giving more
attention to analysing and exploiting the data these
indicators provide;
3. developing more innovative methods of data
collection, analysis and forecasting to better
identify, monitor and understand changing patterns
of drug use.
Geographical diffusion
Although uneven, there is a geographical diffusion of
drug use from cities to towns and rural areas, which
has implications for needs assessment, service
provision and training. Differences in patterns of
diffusion may also improve our understanding of the
distribution of drug behaviours at European, local and
regional levels.
Youth culture and drugs
The emergence of Ecstasy illustrates clearly the need
for analysis of drug trends to occur in the context of
wider social and economic trends, in particular those
that relate to youth culture. Similarly, the role of young
people in the consumer market for recreational
products, including drugs, must be considered.
Social exclusion, drug use, drug problems
Social exclusion, marginalisation, minorities and
migration are often intertwined with drug trafficking, drug
use and drug-related problems, though the relationship is
neither simple nor unidirectional. Developing effective
strategies to respond to drug problems requires a broader
and more thorough analysis.
Drug-related crime and public safety
Little information is provided on this in national reports,
yet a 1996 EMCDDA pilot project indicated that
considerable local information exists, although it may be
hard to find. If questions about drug-related crime or
public safety measures are to be addressed, then the
availability and quality of information must be improved.
Drug markets, availability and supply
The main focus of the Centre’s work in epidemiology
has been on the demand for drugs. This will remain a
central theme, but it will be necessary to pay more
attention to supply and to drug markets, which is
where demand and supply meet.
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Indicators of prevalence, consequences
and patterns of use
General population surveys
• Differences between countries do exist, but
should be treated with caution as a result of
methodological factors, sampling issues and
contextual factors.
• Lifetime use of cannabis is reported by between
5 and 7 % (in Finland and Belgium (Flanders)) to
20 to 30 % in Denmark, Spain and the United
Kingdom, with higher levels for younger adults
(10 to 40 %). Lifetime experience of ampheta-
mines ranges from 1 to 9 % (although most coun-
tries are in the range 1 to 4 %), for cocaine from 1
to 3 %, and for Ecstasy from 0.5 to 3 %. All figures
are higher for younger adults.
• For recent use (last 12 months) cannabis is re-
ported by 1 to 9 %, lowest in eastern Germany,
Finland and Sweden and highest in Spain and
the United Kingdom.
by 1 to 10 %. The lowest figures are for cocaine 
(1 to 3 %) and heroin (1 to 2 %).
• Trend data suggest a gradual increase in the life-
time use of cannabis, increases for amphetamines
and Ecstasy and a small increase for cocaine.
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Figure 1: Cannabis use in the adult population
School surveys
• In this age group, age variations and social con-
text may influence results substantially — for in-
stance, in Finland 5 % of 15- to16-year-olds report-
ed lifetime cannabis use in the same year that
30 % of 17- to18-year-olds in Helsinki reported
ever having used cannabis. Therefore, individual
school surveys must be interpreted with caution.
• Lifetime cannabis use of 15- to 16-year-olds
ranges from 3 to 5 % (Finland, Greece and Portu-
gal) to around 40 % (Ireland and the United King-
dom). In most countries solvents are the second
most commonly abused substance, with lifetime
use ranging from around 3 % (Belgium, Luxem-
bourg and Spain) to 20 % in the United Kingdom.
• Amphetamines have been used by 1 to 13 % of
15- to 16-year-olds, Ecstasy by 1 to 9 % and LSD
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Figure 2: Drug use among 15- to 16-year-old
school students (ever used)
Estimates of problem drug use
• Estimates are more reliable at local than at na-
tional level because of the sometimes large dif-
ferences in prevalence within a country and lack
of national data.
• Estimates of problem drug use for different cities in
Europe range from 1.8 to about 30 (22-39) per
1 000 inhabitants aged 15 to 54 in smaller cities and
from about 3.5 (3.2-3.9) to 14.1 per 1 000 in larger
cities. Although methods and definitions differ be-
tween studies, these figures suggest important dif-
ferences in prevalence of problem drug use.
• Estimates for countries show less extreme varia-
tion, ranging from about 3 (1.8-3.6) to about 9
(8.0-9.7) per 1 000 population aged 15 to 54.
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Figure 3: National prevalence estimates 
of problem drug use 
• The character of problem drug use differs be-
tween countries with mainly opiate addiction in
southern and western Europe, but mainly am-
phetamine injection in northern countries.
Demand for treatment
• Treatment demand data are a useful indirect in-
dicator of problem drug use — with opiates
representing 70 to 95 % of treatment admis-
sions in all countries other than Finland (35 %)
and Sweden (39 %). In these latter countries
amphetamine problems are commonly encoun-
tered.
• Cocaine use is usually reported by less than 5 %
of treatment seekers, although this rises to 11 %
in Luxembourg and 16 % in the Netherlands.
Cocaine is also reported as a secondary drug
problem by many opiate users.
• Cannabis accounts for 2 to 16 % of treatment
cases. In most countries the proportion ranges
from 2 % to about 10 % but rises to 13 % in Ger-
many and 16.5 % in Finland.
• Amphetamines are reported by 1 to 2 % of ad-
missions in most countries but by as many as
39.5 % in Finland and 24.4 % Belgium (Flan-
ders).
• Most treatment seekers are male (70 to 90 %), in
their 20s or 30s. The mean age of drug users in
treatment is still slightly rising in most of the
countries.
• Prevalence of injection among clients admitted
to treatment varies substantially between coun-
tries, ranging from 10 to 15 % to more than 80 %.
The proportion of injectors is decreasing in most
countries.
Deaths and mortality
• Cross-national comparisons are difficult as coun-
tries use different types of registries and record-
ing procedures. The EMCDDA is working to im-
prove comparability of these data.
• Opiate injectors have a 20 to 30 times greater
risk of dying than the general population of the
same age (from overdose, infectious diseases,
suicide or accident).
• Most deaths from acute intoxication involve opi-
ates, although alcohol and benzodiazepines are
also frequently found.
• Although deaths related to Ecstasy have 
received much publicity, deaths related to syn-
thetic drug use are few in number.
• After sharp earlier rises, most EU countries have
shown stabilisation or decrease in acute drug-
related deaths although the increase continues
in some countries.
• Interpreting changes in death rates is complicat-
ed by changing patterns of use which may or
may not result from targeted interventions. In
addition, changes in definitions and recording
procedures may interfere with real trends.
Infectious diseases
• HIV infection rates in injecting drug users (IDUs)
vary from 0 to 30 % between countries, and even
more between regions and cities. The explana-
tion for this relates to both time of introduction
of the virus, impact and timeliness of interven-
tions, and behaviour change of IDUs.
• Prevalence of HIV among IDUs is stable or de-
creasing in all EU countries; however young IDUs
continue to be infected.
• Rates of new AIDS cases are strongly declining due
to the new treatments which delay the onset of
the disease.This changes AIDS into an indicator of
treatment uptake rather than of HIV infection.
• Prevalence of hepatitis B ranges from 3 to 75 %
while rates of over 90 % for hepatitis C have been
reported even in countries with low rates of HIV.
• There are an estimated 500 000 IDUs who are
hepatitis C infected in the EU,which may have im-
portant implications for future health care needs.
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Figure 4: Main drug for which clients demanded 
treatment in different EU countries
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Police arrests and prison data
• Data here refer to law enforcement interventions
and so vary according to differences in legisla-
tion, recording procedures and police resources
and priorities within the Member States.
• Arrests have increased in every country since
1985, more than fourfold in Belgium, Greece,
Spain, Portugal, Finland and the United King-
dom. In recent years, these increases accelerated
in many countries, though in Denmark, Ireland,
Italy, Sweden and the United Kingdom they have
stabilised or decreased. In countries which pro-
vided such data, use-related offences are pre-
dominant, ranging from 65 % to over 85 % of all
the offences involved in arrests. In all except Italy,
Portugal, the Netherlands and Sweden, cannabis
is the predominant drug.
Absolute numbers of acute drug-related deaths cannot be directly compared between countries due to differences in definitions and
methods of data collection.
Note that here trends but not numbers are presented.
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Figure 5: Trends in the number of drug-related deaths in EU countries, 1991-96
Three years’ moving averages indexed (1991 = 100) 
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Figure 6: AIDS incidence related to injecting drug
use in countries of the EU
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Figure 7: Hepatitis B and C infection among 
injecting drug users in the EU
n.a.: data not available.
• The quantities of amphetamines and Ecstasy
seized have shown rapid increases in the early
1990s, with a sharp increase in 1996 for Ecstasy.
The United Kingdom, the Netherlands and 
Germany account for the greatest quantities
seized. Seizures of LSD are less common. The price
of amphetamines and Ecstasy has been decreasing
recently while purity varies considerably for both.
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• Few countries have reliable information on drug
use in prison and the type of data vary widely but
estimates suggest that drug users account for 25
to 70 % of the prison population, 20 to 50 % if we
consider problematic drug users.
Drug market indicators — seizures, price, purity
• The total quantity of cannabis seized has been sta-
ble in recent years,with the largest quantities seized
in 1997 being in Spain. In most countries the num-
ber of cannabis seizures, unlike the quantities
seized, are still increasing. Cannabis accounts for a
greater number of seizures than any other drug.
The price of cannabis appears to be relatively stable.
• Since 1991, quantities of heroin seized have fluc-
tuated around 5 to 6 tonnes with the largest
seizures in Germany and the United Kingdom.
After rising steadily between 1985 and 1992, the
number of seizures has since stabilised. The price
of heroin varies significantly within and between
countries, but it seems to be stable. Purity ranges
from under 25 % to over 40 %.
• There have been significant increases in quantity
and number of cocaine seizures since 1994, with
the largest seizures in 1997 being in Spain. The
price of cocaine is relatively stable in most coun-
tries, and purity is generally over 50 %.
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Figure 8: Arrests for drug law offences in EU countries, 1991-96
Three years’ moving averages indexed (1991 = 100)
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Figure 9: Quantities of cannabis, heroin, cocaine and amphetamines seized in EU countries, 1990-96 
Final remark
The trend to multiple drug use, including alcohol
and diverted medicines, as well as the increasing
profile of amphetamines, requires rapid and sensi-
tive assessment and service planning that is flexible
and responsive. Furthermore, the focus needs to be
extended to incorporate the interpersonal, cultural
and demographic substrata of both experimenta-
tion and problem substance use. Finally, the quality
of data must be improved so that interventions can
be more expeditiously targeted and more sensitively
evaluated.
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The EMCDDA defines drug demand reduction as en-
compassing all activities within the health, social,
educational and criminal justice systems that aim to
prevent drug use, to assist and treat drug users, to re-
duce the harmful consequences of drug use and to
promote the social (re)integration of former users.
Demand reduction targets individuals, families,
groups and communities as the basis for a broader
social approach to substance misuse, in which coop-
eration between statutory bodies, individuals and
community groups is a fundamental prerequisite.
General trends show a diversification in the preven-
tion field, employing a two-pronged strategy —
broad education and health promotion targeting
the general population supplemented by specific
actions targeting vulnerable and at-risk groups. As-
sistance to drug users has increasingly taken the
form of differentiated services oriented at the indi-
vidual case, while seeking simultaneous coordina-
tion of existing services and the improvement of
cooperating structures.
In the 1997 report the EMCDDA focuses on projects
and interventions that have received adequate
evaluation, as a quality criterion for determining
policy relevance. The fact that many projects and
programmes are not evaluated is detrimental to
quality assurance in demand reduction. Key areas
of activity in 1997 have included:
Prevention
The target audience for prevention is both young
people perceived to be at risk and young people in
general.
There is increased emphasis on initiating education
programmes at an early age as a means of estab-
lishing protective factors against subsequent drug
use. This is based on a rationale of drug prevention
in the context of healthy living, and extends the fo-
cus to the family, school and the wider community
Demand reduction
(1) Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Luxembourg, Spain, Sweden, UK.
(2) Austria, Belgium, Denmark, France, Ireland, Italy, Luxembourg, Spain, Sweden, UK.
(3) Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Luxembourg, Spain, Sweden, UK.
Note: For Belgium, Ireland and UK, missing data for 1996 have been extrapolated on general trend of other countries.
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Figure 10: Number of synthetic drug seizures in selected EU countries, 1990-96
as key players. However, comprehensive commu-
nity prevention programmes remain rare. Evalua-
tion results provide evidence for improved 
interpersonal relationships, autonomy and resist-
ance to peer pressure as critical protective factors.
Peer projects have shown their utility as a means of
incorporating primary prevention within the leisure
time activities of young people. Although there has
been little evaluation of mass media campaigns,
some evidence suggests that these may have an
awareness-raising effect.The Internet is increasingly
used for dissemination of information.
While much work has already been expended in this
direction, the key to future progress is coordination
and community participation, underpinned by clear
criteria for assessing the objectives and impact of
projects (by process evaluation and outcome 
research).
Early intervention and at-risk groups
Throughout the EU there is an increasing harm 
reduction focus on groups experimenting with 
Ecstasy and other drugs in the dance scene.
Specific measures have included guidelines on 
‘safe raves’, including free drinking water, rest 
areas, information and counselling, as well as the
initiation of on-site testing facilities.
Outreach strategies have accessed at-risk and mar-
ginalised groups, often in the context of natural so-
cial support networks. This has achieved encourag-
ing results both for changing health and risk be-
haviours, in the context of a harm reduction strat-
egy, and in reaching groups experimenting with
drugs at an early stage.
A range of demand and harm reduction strategies
have been employed to reduce the risks of sub-
stance use to young people. These have included
safety measures for raves, outreach approaches
and community projects that attempt to mobilise
local resources in the fight against drug-related
harm.
Prevention of infectious disease
Harm reduction measures have played an important
role in combating the spread of HIV. A range of strate-
gies — from maintenance prescription of substitutes
such as methadone, syringe and needle exchange
schemes, easily accessed (‘low threshold’) services,
and education and information campaigns — have
combined to make a positive impact in a number of
EU countries. However, there is no evidence of an im-
pact on hepatitis C transmission. Tuberculosis infec-
tion among drug users is also of concern.
The prevention of the spread of infectious disease
in drug-using populations has been shown to be
possible if a range of harm reduction strategies are
implemented. Whilst the range available is exten-
sive, it is likely to include substitution treatments,
needle and syringe exchange schemes, aftercare
provision and a range of matched facilities that are
easily accessed.
Substitution and treatment programmes
Increases in the availability of substitute pro-
grammes in many EU countries have been accom-
panied by the need for consistency in provision and
clear markers for outcome effectiveness (for esti-
mates of Member States’ substitute prescribing see
below). Although the efficacy of methadone in
terms of health and social integration is recognised,
the expanding practice of substitution treatment
might have brought with it issues of quality control.
In addition to methadone, a number of alternatives
are currently explored in several European countries
— LAAM, buprenorphine and prescribed heroin. All
EU countries recognise the importance of a range of
substitution and drug-free out-patient and residen-
tial treatment options, matched to individual needs.
There is also widespread recognition of the need for
effective aftercare, and cooperation between treat-
ment facilities and general health and social service
providers. Finally, the need for primary health care
delivery to drug users has been recognised and col-
laborative programmes with general practitioners
and hospitals have developed.
The effectiveness of interventions requires consid-
erably greater evaluation both between and within
Member States. While we know that drug treat-
ments work, they should be matched to individual
needs and they must be provided within a broader
framework of community involvement and after-
care provision.
Criminal justice policy
In addition to their traditional role in supply reduc-
tion, the police are increasingly involved in demand
reduction and education, and in strategies to sup-
port community partnership. All EU members pro-
vide alternatives to custody for drug offenders,
based on diversion of the individual from prison to
treatment, or to work in the community. A number
of projects have explored training and rehabilita-
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tion as alternatives, while some countries employ
compulsory treatment for addicted offenders. Com-
parisons between the prevalence of drug users in
prison are complicated by differing definitions and
criteria for addiction but are generally in the range
of 15 to 50 %. Drug-free as well as substitution pro-
grammes are becoming increasingly common in
prisons and have shown some success.
There is widespread recognition of the need for al-
ternatives to custody for drug users especially for
first or minor offences, with treatment options in
prison complementing alternatives to custody.
These schemes have been cost-effective and are
sensitive mechanisms for providing alternatives to
the drug escalations (and consequent public health
concerns) that have occurred when addicts are sim-
ply incarcerated.
Specific target groups
A number of countries have recognised the need
for gender-specific approaches to prevention, while
facilities that address the specific treatment needs
of women — motherhood, sexual violence and
prostitution — are becoming increasingly common
throughout Europe. Some countries have attempt-
ed to address the needs of addicts from particular
ethnic and cultural backgrounds. Finally provision
for the care of children of users has also become in-
creasingly significant in prevention and treatment
programmes.
The need to tackle addiction problems in a sensi-
tive manner has led to the development of special-
ist facilities and treatment options for those with
specific needs — women, ethnic groups and both
parents and offspring of problem drug users.
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Table 1: Estimated numbers in substitution treatment (generally methadone)
Me
mb
er
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te Est
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ate
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Com
me
nt
Belgium  6 617
Denmark  2 400
Germany 60 000 40 000 methadone / 20 000 codeine
Greece     400
Spain 51 000
France 46 700 - 56 700 41 000 - 51 000 buprenorphine / 5 700 methadone
Ireland   3 000
Italy 40 864
Luxembourg     158
Netherlands 11 676
Austria 2 966
Portugal  2 324 2 007 methadone / 317 LAAM
Finland     200
Sweden      600
United Kingdom 28 776 Notified addicts receiving substitution treatment in 1996
Total More than 265 664
In conclusion, the achievements of 1997 have sup-
ported preceding work in emphasising the need for
community partnership as the foundation for treat-
ing and preventing substance abuse, with evalua-
tion increasingly prominent as the yardstick with
which to assess effectiveness. While much ongoing
work is both admirable and locally successful, coor-
dination and cooperation both within and between
Member States through dialogue and evaluation
are critical to achieving a consistently high stan-
dard of service provision.
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Scope
The countries covered are: Albania, Bosnia and
Herzegovina, Bulgaria, the Czech Republic, Estonia,
FYROM (the former Yugoslav Republic of Macedo-
nia), Hungary, Latvia, Lithuania, Poland, Romania,
the Slovak Republic and Slovenia. Information is
based on national and international research, ex-
pert missions, and national and city-reports provid-
ed by the central and east European countries
(CEECs) for the European Commission, mainly for
the PHARE multibeneficiary programme for the fight
against drugs, and international organisations
(WHO, UNDCP, Council of Europe).
Historical and current patterns of drug use
Illicit drug use within CEECs became a matter of
concern only after the political changes of the early
1990s. However, some countries (Poland, Hungary,
Slovenia, the former Czechoslovakia) had identified
drug use as a problem before this, developing some
research and treatment strategies.
In the late 1970s the use of domestically produced
drugs was reported in some CEECs (Bulgaria,
Czechoslovakia, Lithuania, Latvia, Hungary and
Poland). The misuse of pharmaceutical drugs was
common during this same period in former
Czechoslovakia, Hungary and Poland, and to a less-
er extent in Bulgaria. More recently, it has also
emerged as a problem in Albania, Bosnia and
Herzegovina and the former Yugoslav Republic of
Macedonia. The political changes in the region in
the early 1990s led to an increase not only of drug
trafficking through many CEECs, but also increased
domestic consumption of imported drugs.
Specific trends for individual drugs
The ESPAD (European school-survey project) study
conducted in 1995 under the auspices of the Pompi-
dou Group of the Council of Europe included seven
The nature and extent of drug use in central and eastern Europe
Table 2: Lifetime cannabis use by schoolchildren (15-16 years old)
Cou
ntr
y
Sam
ple
siz
e Bo
ys Gir
ls
(%)
Czech Republic 2 962 25 18
Estonia 3 118 10   5
Hungary 2 571   5   4
Lithuania 3 196   2    1
Poland 8 940   2   5
Slovak Republic 2 376 12   6
Slovenia 3 306   4 12
(%)
CEECs (Czech Republic, Estonia, Hungary, Lithuania,
Poland, Slovak Republik, Slovenia) and provided
valuable information on drug use amongst 15- to
16- year-old students in these countries. It highlight-
ed cannabis as the most frequently used drug
amongst adolescents and young adults within the
seven participating CEECs.
In the same survey solvents were shown to be the sec-
ond most prevalent substance of misuse. Since the
early 1990s, many CEECs have experienced an in-
crease in heroin consumption (Bulgaria, the Czech 
Republic, the former Yugoslav Republic of Macedonia,
Hungary, Slovak Republic and Slovenia). More recent
trends have shown a gradual move towards the injec-
tion of imported heroin (see Table 3 below).The use of
pharmaceutical drugs in combination with illicit drugs
has become more common in recent years in Bulgaria,
Bosnia and Herzegovina, the former Yugoslav Repub-
lic of Macedonia, Hungary, Slovak Republic and Slove-
nia. The level of cocaine use is still low, although
seizures suggest an increase in trafficking in Poland,
the Czech Republic, Hungary and Romania.
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The legal response
Efforts are being made by the CEECs to adapt their
legislation to meet EU standards in law. All have
adopted new legislation in the drug field (most dat-
ing from 1996 onwards). Drug production and traf-
ficking is a crime with penal sanctions in all countries,
although illicit drug use, in general, is not. All coun-
tries except Albania are signatories to the three UN
Conventions on narcotic drugs, psychotropic sub-
stances and illicit trafficking and all have ratified them
except Estonia which has not yet ratified the 1988
Convention.
Inter-ministerial bodies
All countries, except Bosnia and Herzegovina and
Romania, have established an inter-ministerial body
on drugs for planning and coordinating drug con-
trol efforts between different ministries (the inter-
ministerial body in Albania is not operational).With-
in these bodies, working groups at technical level
have been charged with the preparation of new
legislation, of projects and of national programmes
on drugs. As a result a comprehensive, multidiscipli-
nary national programme on drugs has been
adopted in several CEECs.
Table 3: Percentage of users in CEEC cities who primarily use heroin 
Treatment demand — heroin/opiates
(M. Stauffacher, November 1997.  P-PG/Epid (97) 24/draft).
Cou
ntr
y
City
Tre
atm
ent
de
ma
nd %
(1996)
Bulgaria Sofia   449 95 up 63 down
Bulgaria Varna    70 86 up 73 stable
Czech Republic Prague   634 38 up 72 stable
Hungary Szeged   378 52 stable 50 up
Poland Gdansk   955 77 stable 77 stable
Poland Warsaw 1 023 57 down 59 down
Slovak Republic Bratislava   829 95 stable 86 up
Slovenia Ljubljana   139 69 stable 84 down
Primary drug
heroin
(1994-96)
IV injection
(1994-96)
Tre
nd % Tre
nd
Drug demand reduction
The history of drug demand reduction varies across
the region. It has been implemented in Poland for
over two decades, but for only a few years in Rom-
ania. In general drug demand reduction is still a low
priority in most CEECs, which allocate greater re-
sources to law enforcement (supply reduction).
Treatment in hospital settings, by psychiatrists and
other health professionals predominates. In most
CEECs treatment services are available only in the
largest cities. Out-patient drug-free and long-term
residential treatment are developing at a fast rate in
the majority of CEECs. Prevention is a top priority in
most national strategies and programmes, including
school-based education and health promotion.
Within the last few years, outreach and harm reduc-
tion services have been added to drug demand re-
duction strategies. Although the availability of sub-
stitution programmes (methadone maintenance)
and needle exchange schemes has increased
throughout the region, such harm reduction op-
tions are still rarely available, even in major cities.
Non-governmental organisations often remain un-
derutilised and underfunded. The main needs are
for a strengthening of capacity and performance,
enlargement of funds and for improved communi-
cation and cooperation with governmental organi-
sations.
Synthetic drugs
Almost all countries report an increase in seizures,
but reports on use remain largely anecdotal.
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Changes in legislation have to be interpreted in the
context of a balanced approach between demand
and supply reduction activities and the role of alter-
native sanctions and cooperative approaches in
tackling drug problems in the EU.
Specific legislative developments are outlined with
particular emphasis placed on the distinction be-
tween medical and therapeutic approaches to the
fight against crime linked to traffic, and specific re-
sponses to cannabis control, the profile of which as
a focus for public and policy debate intensified in
1997 throughout the Member States. In individual
cases and under certain circumstances certain EU
countries tolerate cannabis consumption and pos-
session while, in practice, others apply less severe
penalties for cannabis offences. All Member States
resolutely combat crime linked to the trafficking of
cannabis.
Anti-drud action is located within national structures
in which legal responses are drug-specific or generic
(i.e. the legal response to all illicit drugs is uniform).
However,even those countries whose laws do not dif-
ferentiate by substance tend to have implementation
procedures that are sensitive to the circumstances
and to the type or quantity of the illicit substance in-
volved. Thus, in certain European countries penalties
are, in part, determined by categorisation of the
seizure into one of three quantity bands, and posses-
sion of small quantities for personal use, is more likely
to result in a warning or alternative measures than in
prosecution.Table 4 highlights Member States’policy
with regard to the use of cannabis:
National strategies
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Portugal • Each drug has an official daily dose limit.
• Possession is a criminal offence. Small quantities may be regarded as a crime of use and therefore be punished
less severely with an ‘exemption from punishment’ (which is nevertheless registered in the criminal record) if
it is proven that they are for personal use only and that the individual is an occasional user.
• Possession of more than three times the official daily dose limit is punished more severely depending on
whether it occurs for  trafficking or exclusively for personal use.
Sweden • Possession and use of cannabis are prohibited.
• Penalties are defined according to the quantities involved.
• Use of cannabis is sentenced with a fine. On a voluntary basis the fine could be exchanged for counselling.
United Kingdom • Controlled substances are divided in three classes, A, B and C.
• Possession of up to 30g of cannabis (a class B drug) carries a maximum sentence of five years in prison.
• Maximum sentence of 14 years for dealing in cannabis.
• Courts may also use caution, probation or community service.
Table 4: Member States’ policy with regard to the use of cannabis
Austria • Withdrawal of reports in case of first consumption of cannabis.
• Penalties are defined according to the quantity of drug involved. Petty crimes (small quantity) fine and/or up
to six months of imprisonment.
Belgium • Possession and cultivation for personal use less likely to be punished.
• To use in public, incite use, sell or traffic remain serious offences.
Denmark • No formal distinction between drugs.
• A first offence results in entry in central criminal register.
• Subsequent offences result in fines or penalties.
• Recommendation of cautions for possession of small quantities.
Finland • Use sentenced with a fine, or a maximum of two years’ imprisonment.
• In the application of penalties no distinction is made between drugs. However, Finnish law contains the
concept of ‘very dangerous drug’, which refers to a narcotic drug which may cause death by overdose or
serious damage to health.
France • No legal distinction between drugs, the use of which can result in a fine and/or up to one year imprisonment.
Medical treatment and social care for heavy cannabis users, acceptance of treatment being an alternative to
penalties.
• Warning for first offence of cannabis use, if use is occasional and the user socially integrated.
Germany • Possession of small quantities for personal use is a criminal offence, but will not be prosecuted/punished  as
long as there is no harm to third persons.
Greece • No distinction made between soft and hard drugs.
• It is considered that use can result in psychological and/or physical dependence, acts as a ‘gateway drug’ and a
risk to society.
Ireland • Distinction made between possession for personal use and possession with intent to supply.
• Fines for possession of cannabis for personal use for first or second offences.
Italy • Warning for first offence of possession for personal use.
• Subsequent offences involving personal use result in administrative sanctions (suspension of driving licence,
gun licence or passport).
Luxembourg • No distinction between soft and hard drugs, but courts distinguish between:
• users who are not usually prosecuted but receive treatment or a warning on the first occasion, and
• dealers  who are pursued with repressive measures.
Netherlands • Consumption and possession of up to 5g allowed in coffee shops.
• Directives specify terms and conditions for possession and use.
Spain • Possession and use in public places is sanctioned by administrative measures.
• Distinction is made between drugs which cause serious health problems and those that do not, for cultivation
and dealing.
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Early warning system on new synthetic drugs
In June, the Council of the EU adopted a joint action aiming at the creation of an early warning system on new synthetic
drugs and the assessment of their risks so that the
controls on psychotropic substances applicable in the
Member States could be applied equally to new
synthetic drugs. The EMCDDA and the EDU have been
mandated to collect the required information and to
participate in the scientific committee (an extension of
the EMCDDA scientific committee) tasked with
assessing the possible risks caused by the use of and
traffic in new synthetic drugs.
With no substantial political or organisational changes
in the EU, the third European action plan to combat
drugs remains the general framework for anti-drug ac-
tion with regard to the new framework established by
the Treaty of Maastricht to combat drugs in an inte-
grated approach.This focuses on three areas: demand
reduction,supply reduction and international cooper-
ation,with reinforced cooperation between drug poli-
cies. Reliable and scientifically based information is in-
creasingly considered an essential prerequisite for any
effective strategy against drugs. The most significant
developments in 1997 relate to targeted areas of ac-
tivity, changes in internal funding arrangements and
developments in external funding.
Areas of activity. The most significant measure
within the demand reduction area was the imple-
mentation of the Community action programme on
the prevention of drug dependence, which aimed to
encourage cooperation between Member States
and support their efforts. Actions will be promoted
in the area of data collection, research and evalua-
tion and in the field of information, health education
and training. In 1997, 22 prevention projects have
been supported. Further demand reduction activi-
ties related to the reintegration of addicts (through
the Employment-Integra initiative) and a proposal
to reduce the incidence of driving while under the
influence of alcohol, medicines or illicit drugs. The
major supply reduction initiatives related to moni-
toring of trade in chemicals used in the manufacture
of illicit drugs (‘precursors’) and increased emphasis
on anti-money-laundering strategies. Within a gen-
eral initiative promoting international cooperation,
the multi-country PHARE programme for the fight
against drugs monitors the drug control efforts of
the 10 CEECs currently preparing for accession to
the EU. A regulation setting down the principles,
objectives and modalities of the EU/North-South co-
operation in the drugs field was adopted and en-
tered into force (Regulation (EC) No 2046/97 of 13
October 1997). In June 1997, the Amsterdam Treaty
reinforced Community actions to reduce drugs-re-
lated health damage, including information and pre-
vention to consolidate new objectives and Commu-
nity action on security and justice.
Internal funding activity. In 1997, at a cost of ECU
33 million, the EU supported eight budget lines,
three of which were specific to drugs.These were the
programme of Community action on the prevention
of drug dependence (with an annual budget of ECU
4.9 million of which 69 % was spent to support Euro-
pean networks), global aspects of the fight against
drugs (with an annual budget of ECU 1.2 million,
67 % of which was spent on supply reduction), and
EMCDDA (with an overall budget of ECU 6.3 million,
which supports research, training and information
production, analysis and exchange). The other major
areas of internal spending are on the Employment-
Integra programme for the reintegration of addicts
(ECU 18.4 million), cooperation in the field of justice
and home affairs (ECU 4.5 million) and the Biomed
research programme on neuro-physiological aspects
of addiction (ECU 1 million).The total figure for inter-
nal spending in 1997 was ECU 33.3 million, an in-
crease on the ECU 15.2 million spent in 1996.
External spending activities. There were two spe-
cific drug-related budget lines funded in 1997. They
were for:
• North-South cooperation (ECU 8.9 million to fund
demand reduction, the law enforcement efforts
and chemical precursor controls in Latin America,
Asia, the Caribbean and Africa, and the Mediter-
ranean region);
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• the PHARE multi-country programme for the
fight against drugs (ECU 5.0 million to establish
information systems, to create money-launder-
ing legislation, to make precursor control com-
patible with the EU, to develop demand reduc-
tion strategy and for staff training).
Non-specific budget lines for drug-related projects
totalled ECU 6.2 million in 1997, of which 92 % was
spent in the African region and 8 % in the Caribbean
region. 81 % of the total was dedicated to demand
reduction projects.
Overall, more than ECU 53 million was spent on
drug-related actions in 1997 — 62 % for actions
within the EU, and 38 % on actions outside. Within
the EU, the vast majority was spent on rehabilita-
tion actions, while outside the EU, 60 % of the ex-
ternal budget was spent on the African and CEEC
regions. This represents a slight decrease on the 
total of ECU 61 million spent in 1996, with the 
proportion for internal spending having increased
considerably since 1996.
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Chart 2: External drug-related Community expenditure according to the field of interest
Chart 1: Analysis of internal spending %
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International action in the drug field is charac-
terised by the role and activities of key organisa-
tions involved in tackling drug issues at an inter-
national level, and their activities and achieve-
ments in 1997. Reports on patterns and trends in
seizures of specific narcotics and psychotropic
substances are also among the important indica-
tors in 1997.
Advances in 1997
With Austria becoming a signatory in 1997, all EU
Member States have now signed the UN interna-
tional drug control treaties. A key development was
the preparation of the UN General Assembly Spe-
cial Session (Ungass) on illicit drugs (8 to 10 June),
at which the UNDCP adopted an important political
declaration and an unprecedented demand reduc-
tion declaration. The UNDCP published its first
‘World drugs report’. The WHO continued to devel-
op its programme on substance abuse, while Inter-
pol transmitted over two million messages relating
to criminal activity in the course of the year and
held a general assembly meeting at which 18 reso-
lutions, including anti-money-laundering resolu-
tions, were passed. The World Customs Organisa-
tion (WCO) reported an increase in detections of
drugs of more than 10 % from 1996.
Changes in drug supply to the EU 
Despite increased law enforcement efforts, the
drug supply is still increasing, as indicated by price
stability and availability. In 1997, there were signifi-
cant increases in cocaine and amphetamine
seizures, a slight increase in seizures of cannabis
resin (hashish) and small decreases in heroin and
cannabis leaf (marijuana) seizures. While trafficking
routes have remained largely unchanged, there has
been an increase in the production and trade of
new synthetic drugs in EU and east European coun-
tries, with some evidence of export of synthetic
drugs to other regions. According to Interpol, about
800 tonnes of cocaine and 450 tonnes of heroin are
produced annually worldwide. Much of this ends
up in the EU (38 tonnes of cocaine and 4.4 tonnes
of heroin were seized in the European Union in
1997 in accordance with data provided by the Eu-
ropol drugs unit)
International players
International players on the drugs scene can be di-
vided into three categories:
• United Nations. The UN has established a number
of bodies to deal with drug issues which are re-
sponsible for monitoring the implementation of
international treaties.Specifically, the INCB (the In-
ternational Control Board) is the independent and
quasi-judicial organ responsible for how interna-
tional drug control conventions are implemented
and monitored; the CND (Commission on Narcotic
Drugs) is the central policy-making body within
the UN for all questions related to drug control;
and the UNDCP (United Nations Drug Control Pro-
gramme) acts as the secretariat for both the CND
and INCB, assisting Member States in implement-
ing the decisions of the policy-making bodies. In
addition, the UN’s World Health Organisation
(WHO) promotes public health and better living
conditions. A number of other specialist UN bod-
ies are also involved in drug control issues.
• Other international agencies. Interpol promotes
international cooperation in the enforcement of
laws curbing illicit drug production, manufacture
and trafficking. Links between the EMCDDA and
Interpol, established in 1995, are to be strength-
ened. The World Customs Organisation (WCO) 
attempts to harmonise customs procedures and
to increase the effectiveness of targeting drug
consignments.
• Regional organisations. The Council of Europe’s
Pompidou Group promotes a multidisciplinary
approach to tackling drug problems on a pan-
European basis, while the Dublin Group is an in-
ternational body for coordinating international
drug control policy. The Inter-American Drug
Abuse Control Commission (CICAD) targets traf-
ficking, production and use and the Financial 
Action Task Force (FATF) targets money-launder-
ing in the financial system.
In conclusion, increased international cooperation
and coordination have continued in 1997 but must
be augmented in future years if the ongoing in-
creases in availability of narcotic drugs and psy-
chotropic substances is to be halted.
International action
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United Nations
International Drug control
programme (UNDCP)
International Narcotics
Control Board
(INCB)
World Health
Organisation
(WHO)
Financial Action
Task Force
(FATF)
Council of Europe
‘Pompidou Group’
CICAD
Dublin Group
Interpol
(ICPO)
World Customs
Organisation
(WCO)
Commission on
Narcotic Drugs
(CND)
UN Commission on
Crime Prevention and
Criminal Justice
European Union
ROLE: UN crime
prevention policy.
EU status: observer.
ROLE: coordination of all UN
drug control activities.
EU status: observer.
EMCDDA-UNDCP: exchange
of data, contribution to
the annual report.
ROLE: evaluation of licit needs
of drugs, international
cooperation.
EMCDDA-INCB: exchange
of data, contribution to
the annual report.
ROLE: health promotion.
EU status: observer.
EMCDDA-WHO: exchange
of data, contribution to
the annual report.
ROLE: money
laundering prevention.
EU status: member.
ROLE: international cooperation
in a pan-European context.
EU status: permanent
correspondent.
EMCDDA-Pompidou Group:
exchange of data, contribution
to the annual report.
ROLE: cooperation
within American states.
EU status: participation
where of mutual
benefit.
ROLE: informal
policy- making body.
EU status: observer.
ROLE: international police
cooperation.
EU status: observer.
EMCDDA-ICPO: exchange
of data, contribution to
the annual report.
ROLE: international
customs cooperation.
EU status: observer.
EMCDDA-WCO: exchange
of data, contribution to
the annual report.
ROLE: drug general
policies, control of
international treaties.
EU status: observer
Table 5: The European Union and the international community in the drugs field
The EMCDDA aims to study the financial impact of
drug policies in the EU and to analyse the break-
down of public spending on drug matters and to
outline approaches allowing a comparative analysis
of public spending effectiveness. The three do-
mains of public spending considered are repression
(concerned with enforcing drug laws), treatment
(particularly around the health costs associated
with AIDS) and prevention.
Spending is divided between that spent directly on
drug projects and spending within ministries and
Analysis of public spending on drugs
public administrations that includes the so-called
anti-drugs effort (although the exact proportion
spent in this way is difficult to calculate).
Table 6 is based on French and Swiss projects, with
data also gathered in Belgium, Denmark, Ireland,
Portugal, Spain and the United Kingdom. The data
exemplify many of the problems of non-availability
of data and lack of comparability between coun-
tries. Thus, data on arrests for ‘drug offences’ may in-
clude either the number of people arrested or the
number of infringements of the law.
A method is outlined for calculating a ‘drug budget’in
which direct spending on drug action is used as the
basis for calculating public administration spending.
The example used, of calculating the allocation of po-
lice time,can also be applied, for example, to expendi-
ture on the judicial system. However for the prison
system the calculation is complicated by the commis-
sion of non-drug crimes either to finance drug act-
ivity or while under the effects of drugs.
The need for a European comparative study on
‘drug budgets’ is identified as a means of assess-
ing the extent of each country’s public spending
effort. The drug budget as a proportion of GDP is
similar in the three European countries studied,
but substantially higher in the United States. As a
proportion of public spending, the figures for the
United States and the United Kingdom are signif-
icantly higher than for France and the Nether-
lands.
In Europe the proportion of the budget allocated to
law enforcement (around 80 % in the three coun-
tries) is significantly lower than in the United States
(93 %). However, in all countries, it is difficult to cal-
culate the amount spent on prevention because of
its decentralised nature. The reinforcing of re-
sources for one budget line tends to be at the ex-
pense of one of the others, as increases in overall
spending are unlikely at times of limited resources.
In conclusion, more analysis will require greater
comparable information from Member States as
the first step in developing a greater understanding
of improved efficiency in public spending on drug
issues and evaluating the social costs generated by
the drug problem.
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Table 6: Public spending and the  ‘drug budget’
(1) Million ECU. 
(2) Kopp and Palle — MILDT report (1996).
(3) Estermann, J., Consommation et trafic de drogues: les coûts de la répression (estimation pour la Suisse 1991).
(4) Tackling drugs together — strategy for England, 1995-98, HMSO, May 1995.
Bel
giu
m
Budget of all national police forces (1) 1 724.71 667.37 3 780.15 620.61 n.a. 3166.43 865.77 12 516.37
Interpellations for drug offences 23 762 13 992 79 271 n.a. 9 333 79 445 42 000 998
Customs budget (1) n.a. n.a. 585.32 65.05 n.a. n.a. n.a. 1 282.28
Budget of the criminal justice system (1) 463.83 1 062.28 3 094.73 894.44 707.12 n.a. n.a. 2 024.92
Number of persons imprisoned for drug offences n.a. 1 282 11 816 225 3 653 9 925 n.a. 6 400
Budget of institutions specialising in treating drug
addiction (1) 69.38 n.a. n.a. 10.09 3.77 94.61 n.a. 273.27
Budgetary lines allocated to drug prevention (1) n.a. n.a. n.a. 0.46 12.14 36.77 n.a. 252.25
Budget of institutions specialising in drug prevention (1) n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Amount spent on research (1) n.a. n.a. 6.35 1.30 n.a. 7.35 n.a. n.a.
Amount spent on international action (1) n.a. n.a. 10.58 0.19 0.01 4.26 n.a. 273.27
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